Taysha Gene Therapies to present on TSHA-102 in Rett Syndrome

Taysha Gene Therapies will present previously disclosed clinical data on its TSHA-102 program in evaluation for Rett syndrome during an oral presentation at the upcoming 9th World Rett Syndrome Congress, taking place in Queensland, Australia from October 2-5, 2024. The presentation will entail previously disclosed clinical data up to 52 weeks from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data up to 22 weeks from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome. The Company expects to provide clinical data from cohort two and a longer-term update on clinical data from cohort one from both the adolescent and adult, and the pediatric REVEAL trials in the first half of 2025.